Business WeeklyDesktop Genetics Introduces New Series of Customizable CRISPR LibrariesLab Manager MagazineLondon, UK – 17 October 2017 – Desktop Genetics Ltd (“the Company”), a company revolutionizing the way biologists use CRISPR genome editing techno… Continue reading
Drug Target Review (press release)CRISPR used to identify drug target for bowel cancerDrug Target Review (press release)Researchers have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conven… Continue reading
Aduro Biotech Announces Presentation of Phase 1 Data for LADD …Markets InsiderBERKELEY, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy …and more &… Continue reading
Longeveron Pioneering Development of Stem Cell Therapies for Aging FrailtyMarkets InsiderMIAMI, Oct. 17, 2017 /PRNewswire/ — Longeveron LLC, a leading life sciences company developing innovative therapies for age-related diseases, announced that the c… Continue reading
|
AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
Business Wire (press release) CHAPEL HILL, N.C.–(BUSINESS WIRE)–Asklepios BioPharmaceutical, Inc. (AskBio) announced today the formation of Viralgen, a gene therapy joint venture with Columbus Venture Partners. The Viralgen Vector Core will use AskBio’s technology for the … |
Weekly Register |
BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q3 2017 Results – Earnings Call Transcript
Seeking Alpha The first patients have been enrolled in the study and we’re also really pleased about the support that we’ve received from CIRM, California stem cell agency to provide funding for this important project. We are working with the top leading ALS centers … BrainStorm Announces Third Quarter 2017 Financial ResultsMarkets Insider BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALSGuruFocus.com (blog) Brainstorm Cell Therapeutics (NASDAQ:BCLI) Getting Somewhat Favorable Press Coverage, Report ShowsThe Ledger Gazette American Consumer News, LLC all 45 news articles » |
|
Your Daily Pharma Scoop: Everybody’s Gilead Problem, Halozyme’s Further Progress, ZIOPHARM’s Gene Therapy
Seeking Alpha ZIOPHARM’s gene therapy Ad-RTS-hIL-12 with veledimex commences trials in pediatric patients with brain tumors. This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare … |